Is Statera Biopharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Statera Biopharma Inc (STAB) is currently classified as HALAL as of January 2023. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Statera Biopharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Statera Biopharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Statera Biopharma Inc?

Muslim investors may consider investing in Statera Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Statera Biopharma Inc classified as HALAL?

Musaffa determines the Shariah status of Statera Biopharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Statera Biopharma Inc updated?

The Shariah compliance status of Statera Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Statera Biopharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Statera Biopharma Inc?

You can check the latest Shariah compliance status of Statera Biopharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

STAB Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: January 04, 2023

Report Source: 2022 3rd Quarter Report

Statera Biopharma Inc. Stock Analysis STAB

United States Health Care Nano Cap Report: Q3, 2022

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Key Statistics of Statera Biopharma Inc (STAB)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

2870.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.03

Market Cap

7142.00

Avg. Volume

8456.95

Dividend Yield

Financial Metrics & Statements of Statera Biopharma Inc (STAB)

FAQ's for Statera Biopharma Inc (STAB)

According to Musaffa’s Shariah screening methodology, Statera Biopharma Inc (STAB) is currently classified as HALAL as of January 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.